E2F-1: A proliferative marker of breast neoplasia

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 4, 2000, Pages 395-401

  Zhang, Shi Yu ^a   Liu, Shao Chen ^a   Al Saleem, Luma F ^a   Holloran, Dana ^a   Babb, James ^a   Guo, Xu ^a   Klein Szanto, Andres J P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; TRANSCRIPTION FACTOR E2F;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER INVASION; CARCINOGENESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALIGNANT TRANSFORMATION; MULTIGENE FAMILY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL DIVISION; DNA-BINDING PROTEINS; E2F TRANSCRIPTION FACTORS; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROGNOSIS; TRANSCRIPTION FACTOR DP1; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0342657680     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Wilkinson, E. J., and Hendricks, J. B. Role of the pathologist in biomarker studies. J. Cell. Biochem. Suppl., 23: 10-18, 1995.
2. Schwartz, G. F., Schwarting, R., Rabindranauth, P., and Finfel, G. C. Clinical applications of serum and tissue markers in malignant disease: breast cancer as the paradigm. Clin. Chem., 39: 2404-2412, 1993.
3. Ravdin, P. M. Prognostic factors in breast cancer. In: G. Bonadonna, G. N. Hortobagyi, and A. M. Gianni, (eds.), Textbook of Breast Cancer - A Clinical Guide to Therapy, pp. 35-63. London: Martin Dunitz Ltd. 1997.
4. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell. 81: 323-330, 1995.
5. Bartek, J., Bartkova, J., and Lukas, J. The retinoblastoma protein pathway and the restriction point. Curr. Opin. Cell Biol., 8: 805-814, 1996.
6. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 274: 1672-1677, 1996.
7. Landberg, G., and Roos, G. The cell cycle in breast cancer. APMIS, 105: 575-589, 1997.
8. Dutta, A., Chandra, R., Leiter, L. M., and Lester, S. Cyclins as markers of tumor proliferation: immunohistochemical studies. Proc. Natl. Acad. Sci. USA, 92: 5386-5390, 1995.
9. Weinstat-Saslow, D., Merino, M. J., Manrow, R. E., Lawrence, J. A., Bluth, R. F., Wittenbel, K. D., Simpson, J. F., Page, D. L., and Steeg, P. S. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nat. Med., 1: 1257-1260, 1995.
10. Oyama, T., Kashiwabara, K., Yoshimoto, K., Arnold, A., and Koerner, F. Frequent overexpression of cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res., 58: 2876-2880, 1998.
11. Zhang, S. Y., Camano, J., Cooper, F., Guo, X., and Klein-Szanto, A. J. P. Immunohistochemistry of cyclin D1 in human breast cancer. Am. J. Clin. Pathol., 102: 695-698, 1994.
12. Barnes, D. M. Cyclin D1 in mammary carcinoma. J. Pathol., 181: 267-269, 1997.
13. Slansky, J. E., and Farnham, P. J. Introduction to E2F family: protein structure and gene regulation. Curr. Top. Microbiol. Immunol., 208: 1-30, 1996.
14. Johnson, D. G., Schwarz, J. K., Cress, W. D., and Nevins, J. R. Expression of transcription factor E2F-1 induces quiescent cells to enter S phase. Nature (Lond.), 365: 349-352, 1993.
15. 1 cyclin-dependent kinase activity. Genes Dev., 9: 2873-2887, 1995.
16. Singh, P., Wong, S. H., and Hong, W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J., 13: 3329-3338, 1994.
17. Johnson, D. G., Cress, W. D., Jakoi, L., and Nevins, J. R. Oncogenic capacity of the E2F1 gene. Proc. Natl. Acad. Sci. USA, 91: 12823-12827, 1994.
18. Saito, M., Helin, K., Valentine, M. B., Griffith, B. B., Willman, C. L., and Harlow, E. Amplification of the E2F-1 transcription gene in the HEL erythroleukemia cell line. Genomics, 25: 130-138, 1995.
19. Suzuki, T., Yasui, W., Yokozaki, H., Naka, K., Ishikawa, T., and Tahara, E. Expression of the E2F family in human gastrointestinal carcinomas. Int. J. Cancer, 81: 535-538, 1999.
20. Yamasaki, L., Bronson, R., Williams, B. O., Dyson, N. J., Harlow, E., and Jacks, T. Loss of E2F-1 reduced tumorigenesis and extends the lifespan of Rb1(+/-) mice. Nat. Genet., 18: 360-364, 1998.
21. Lai, R., Medeiros, L. J., Coupland, R., McCourty, A., and Brynes, R. K. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod. Pathol., 11: 457-463, 1998.
22. Qin, X. Q., Livingston, D. M., Kaelin, W. G., and Adams, P. D. Deregulated transcription factor E2F-1 expression leads to S-phase and p53-mediated apoptosis. Proc. Nat. Acad. Sci. USA, 91: 10918-10922, 1994.
23. Hunt, K. K., Deng, J., Liu, T. J., Wilson-Heiner, M., Swisher, S. G., Clayman, G., and Hung, M. C. Adenovirus-mediated overexpression of the transcription factor E2F-1 induces apoptosis in human breast and ovarian-carcinoma cell lines and does not require p53. Cancer Res., 57: 4722-4726, 1997.
24. Yamasaki, L., Jack, T., Bronson, R., Goillot, E., Harlow, E., and Dyson, N. J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell, 85: 539-548, 1996.
25. Rabbani, F., Richon, V. M., Orlow, I., Lu, M. L., Drobnjak, M. Dudas, M., Charytonowicz, M., Dalbagni, G., and Cordon-Cardo, C. Prognostic significance of transcription factor E2F-1 in bladder cancer: genotypic and phenotypic characterization. J. Natl. Cancer Inst., 91: 874-881, 1999.
26. 1-S transition defects occur in most breast cancers and predict outcome. Breast Cancer Res. Treat., 56: 105-112, 1999.
27. Fernandez, P. L., Jares, P., Rey, M. J., Campo, E., and Cardesa, A. Cell cycle regulators and their abnormalities in breast cancer. Mol. Pathol., 51: 305-309, 1998.
28. American Joint Committee on Cancer. Breast. In: AJCC Cancer Staging Manual, Ed. 5. pp. 171-178. Philadelphia: Lippincott-Raven, 1997.
29. Helin, K., Wu, C., Fattaey, A. R., Lees, J. A., Dynlacht, B., Ngwu, C. and Harlow, E. Heterodimerization of the transcription factor E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev., 7: 1850-1861, 1993.
30. Gerdes, J., Li, L., Schluer, C., Duchrow, M., Wohlenberg, C., Gerlach, C., Stahmer, I., Kloth, S., Brandt, E., and Flad, H. D. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am. J. Pathol., 138: 867-873, 1991.
31. 1 cyclins and cyclin-dependent kinases during tumor progression of chemically induced mouse skin neoplasms. Mol. Carcinog., 18: 142-152, 1997.
32. Allred, D. C., Harvey, J. M., Berardo, M., and Clark, G. M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod. Pathol., 11: 155-168, 1998.
33. Page, D. L., Jensen, R. A., and Simpson, J. F. Premalignant and malignant disease of the breast: the role of the pathologist. Mod. Pathol., 11: 120-128, 1998.
34. Kollias, J., Elston, C. W., Ellis, I. O., Robertson, J. F. R., and Blamey, R. W. Early-onset breast cancer: histopathological and prognostic considerations. Br. J. Cancer, 75: 1318-1323, 1997.
35. Linden, M. D., Torres, F. X., Kubus, J., and Zarbo, L. J. Clinical application of morphologic and immunohistochemical assessments of cell proliferation. Am. J. Clin. Pathol., 10: 565-573, 1992.
36. Leonardi, E., Girlando, S., and Serio, G. PCNA and Ki-67 expression in breast carcinoma: correlation with clinical and biological variables. J. Clin. Pathol., 45: 416-419, 1992.
37. Keshgegian, A. A., and Anaan. A. Proliferation markers in breast carcinoma: mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and Mib-1. Am. J. Clin. Pathol., 104: 42-49, 1995.
38. Gee, J. M. W., Douglas-Jones, A., Hepburn, P., Sharma, A. K., McClelland, R. A., Ellis, I. O., and Nicholson, R. I. A cautionary note regarding the application of Ki-67 antibodies to paraffin-embedded breast cancers. J. Pathol., 177: 285-293, 1995.
39. Querzoli, P., Albonico, G., Ferretti, S., Rinaldi, R., Magri, E., Indelli, M., and Nenci, I. Mib-1 proliferative activity in invasive breast cancer measured by image analysis. J. Clin. Pathol., 49: 926-930, 1996.
40. Ellis, P. A., Makris, A., Burton, S. A., Titley, J., Ormerod, M. G., Salter, J., Powles, T. J., Smith, I. E., and Dowsett, M. Comparison of Mib-1 proliferation index with S-phase fraction in human breast carcinomas. Br. J. Cancer, 73: 640-643, 1996.
41. Jansen, R. L., Hupperets, P. S., Arenas, J. W., Joosten-Achjanie, S. R., Volovics, A., Schouten, H. C., and Hillen, H. F. Mib-1 labelling index is an independent prognostic marker in primary breast cancer. Br. J. Cancer, 73: 640-645, 1998.
42. Thor, A. D., Liu, S., Moore, D. H., II, and Edgerton, S. M. Comparison of mitotic index in vitro bromodeoxyuridine labeling, and Mib-1 assay to quantitate proliferation in breast cancer. J. Clin. Oncol., 17: 470-477, 1999.
43. Haerslev, T., Jacobsen, G. K., and Zedeler, K. Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res. Treat., 37: 101-113, 1996.
44. van Dierendonck, J. H., Wijsman, J. H., Keijzer, R., van de Velde, C. J. H., and Cornelisse, C. J. Cell-cycle-related staining patterns of anti-proliferating cell nuclear antigen monoclonal antibodies: comparison with BrdU labeling and Ki-67 staining. Am. J. Pathol., 138: 1165-1172, 1991.
45. van Diest, P. J., Michalides, R. J., Jannink, I., van der Valk, P., Peterse, H. L., de Jong, J. S., Meijer, C. J. L. M., and Baak, J. P. A. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am. J. Pathol., 150: 705-711, 1997.
46. McIntosh, G. G., Anderson, J. J., and Milton, I. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene, 11: 885-891, 1995.
47. Michalides, R., Hageman, P., and van Tinteren, H. A clinicopathological study on overexpression of cyclin D1 and p53 in a series of 248 patients with operable breast cancer. Br. J. Cancer, 73: 728-734, 1996.
48. Gillette, C., Smith, P., Gregory, W., Richards. M., Millis, R., Peters, G., and Barnes, D. Cyclin D1 and prognosis in human breast cancer. Int. J. Cancer, 69: 92-99, 1996.
49. Kinne, D. M. Staging and follow-up of breast cancer patients. Cancer (Phila.), 67: 1196-1198, 1991.